GSK Shoulder-To-Shoulder With CureVac Over COVID-19 Vaccine U-Turn
Focus On Second-Generation After EMA Filing Withdrawal
The UK major is delighted with the German biotech's decision to throw in the regulatory towel with CVnCoV and concentrate on the firms' collaboration to development a second-generation COVID-19 vaccine. However, GSK is insisting that the partners look at both modified as well as unmodified mRNA approaches, a significant change of strategy for CureVac.
